Literature DB >> 29708118

Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine.

Peng Shen1, Wenzhao Zhong2.   

Abstract

Entities:  

Year:  2018        PMID： 29708118      PMCID： PMC5906233          DOI： 10.21037/jtd.2018.03.97

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  31 in total

1.  Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version).

Authors:  Xiu-Yi Zhi; Jin-Ming Yu; Yuan-Kai Shi
Journal:  Cancer       Date:  2015-09-01       Impact factor: 6.860

2.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

3.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

Authors:  Antonio Marchetti; Carla Martella; Lara Felicioni; Fabio Barassi; Simona Salvatore; Antonio Chella; Pier P Camplese; Teodorico Iarussi; Felice Mucilli; Andrea Mezzetti; Franco Cuccurullo; Rocco Sacco; Fiamma Buttitta
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

4.  Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.

Authors:  Ning Li; Wei Ou; Xiong Ye; Hai-Bo Sun; Liang Zhang; Qin Fang; Song-Liang Zhang; Bao-Xiao Wang; Si-Yu Wang
Journal:  Ann Surg Oncol       Date:  2014-03-01       Impact factor: 5.344

Review 5.  Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.

Authors:  Mark G Kris; Laurie E Gaspar; Jamie E Chaft; Erin B Kennedy; Christopher G Azzoli; Peter M Ellis; Steven H Lin; Harvey I Pass; Rahul Seth; Frances A Shepherd; David R Spigel; John R Strawn; Yee C Ung; Michael Weyant
Journal:  J Clin Oncol       Date:  2017-04-24       Impact factor: 44.544

6.  Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

Authors:  R Arriagada; A Auperin; S Burdett; J P Higgins; D H Johnson; T Le Chevalier; C Le Pechoux; M K B Parmar; J P Pignon; R L Souhami; R J Stephens; L A Stewart; J F Tierney; H Tribodet; J van Meerbeeck
Journal:  Lancet       Date:  2010-03-24       Impact factor: 79.321

7.  Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.

Authors:  Ying Cheng; Haruyasu Murakami; Pan-Chyr Yang; Jianxing He; Kazuhiko Nakagawa; Jin Hyoung Kang; Joo-Hang Kim; Xin Wang; Sotaro Enatsu; Tarun Puri; Mauro Orlando; James Chih-Hsin Yang
Journal:  J Clin Oncol       Date:  2016-08-09       Impact factor: 44.544

8.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

9.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396
View more
  3 in total

1.  Genetic alteration profile of EGFR-mutant resected IIB-IIIA stage NSCLC and correlation to clinical outcomes.

Authors:  Qiuhua Deng; Yuan Qiu; Junmei Jia; Hailing Tang; Liping Liu; Liyan Huang; Dongyun He; Xiaomeng Dong; Haihong Yang
Journal:  Transl Lung Cancer Res       Date:  2019-12

2.  Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study.

Authors:  Ziqing Zeng; Bo Yan; Yulong Chen; Lianmin Zhang; Jianquan Zhu; Fan Yang; Feng Wei; Terence Chi Chun Tam; Diego Kauffmann-Guerrero; Ross Andrew Soo; Xiubao Ren; Jian You
Journal:  Transl Lung Cancer Res       Date:  2020-12

3.  Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study.

Authors:  Xue-Ning Yang; Hong-Hong Yan; Jun Wang; Xiang-Yang Chu; Zhi-Dong Liu; Yi Shen; Hai-Tao Ma; Xiang-Ning Fu; Jian Hu; Nai-Kang Zhou; Yong-Yu Liu; Xin-Ming Zhou; Jing-Song Li; Kang Yang; Jian Li; Lin Xu; Si-Yu Wang; Qun Wang; Lun-Xu Liu; Shun Xu; Zhong-Yuan Chen; Hong-He Lou; Chang-Li Wang; Ying Cheng; Si-Yang Liu; Xu-Chao Zhang; Wen-Zhao Zhong; Yi-Long Wu
Journal:  JTO Clin Res Rep       Date:  2021-11-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.